Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor EML4-ALK

New Guidelines to Evaluate the Response to Treatment in Solid Tumors

2000 • 15,583 citations

Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib

2004 • 11,185 citations

EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

2004 • 9,201 citations

Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer

2006 • 5,595 citations

Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer

2007 • 5,137 citations

Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer

2002 • 4,805 citations

COMPARISON OF FOUR CHEMOTHERAPY REGIMENS FOR ADVANCED NON-SMALL-CELL LUNG CANCER

2002 • 3,803 citations

Clinical and Biological Features Associated With Epidermal Growth Factor Receptor Gene Mutations in Lung Cancers

2005 • 2,285 citations

Global Survey of Phosphotyrosine Signaling Identifies Oncogenic Kinases in Lung Cancer

2007 • 2,249 citations

Erlotinib in Lung Cancer — Molecular and Clinical Predictors of Outcome

2005 • 1,834 citations

KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib

2005 • 1,510 citations

Mutations in the Epidermal Growth Factor Receptor and in KRAS Are Predictive and Prognostic Indicators in Patients With Non–Small-Cell Lung Cancer Treated With Chemotherapy Alone and in Combination With Erlotinib

2005 • 1,467 citations

EML4-ALKFusion Gene and Efficacy of an ALK Kinase Inhibitor in Lung Cancer

2008 • 939 citations

The anaplastic lymphoma kinase in the pathogenesis of cancer

2007 • 841 citations

First-Line Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer Harboring Somatic EGFR Mutations

2008 • 802 citations

The EML4‐ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild‐type EGFR and KRAS

2009 • 700 citations

Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma

2007 • 640 citations

The 2004 World Health Organization classification of lung tumors

2005 • 550 citations

Prospective Phase II Study of Gefitinib for Chemotherapy-Naïve Patients With Advanced Non–Small-Cell Lung Cancer With Epidermal Growth Factor Receptor Gene Mutations

2006 • 507 citations

A mouse model for EML4-ALK -positive lung cancer

2008 • 498 citations

Multiplex Reverse Transcription-PCR Screening for EML4-ALK Fusion Transcripts

2008 • 480 citations

Global and regional estimates of cancer mortality and incidence by site: II. results for the global burden of disease 2000

2002 • 474 citations

EML4-ALK Fusion Is Linked to Histological Characteristics in a Subset of Lung Cancers

2008 • 465 citations

Genomic Alterations of Anaplastic Lymphoma Kinase May Sensitize Tumors to Anaplastic Lymphoma Kinase Inhibitors

2008 • 401 citations

Distinct Epidermal Growth Factor Receptor and KRAS Mutation Patterns in Non–Small Cell Lung Cancer Patients with Different Tobacco Exposure and Clinicopathologic Features

2006 • 398 citations

A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations

2006 • 280 citations

EML4-ALK Fusion Lung Cancer: A Rare Acquired Event

2008 • 252 citations

EML4-ALK fusion transcripts, but no NPM-, TPM3-, CLTC-, ATIC-, or TFG-ALK fusion transcripts, in non-small cell lung carcinomas

2008 • 165 citations

EML4–ALK fusion transcript is not found in gastrointestinal and breast cancers

2008 • 64 citations